Recently, it has been demonstrated that both siRNA-mediated and pharmaceutical PARP inhibition leads to an increase in phosphorylation of STAT3 in ovarian cancer cell lines through dePARylation, a critical intrinsic property of PARP blockade, which is responsible for PD-L1 upregulation (17). Here, PARP1 is linked to ovarian cancer.